Apr 30, 2018 by Brian Orelli, PhDVertex Pharmaceuticals Takes a Detour Around the FDA's RoadblockThe news shouldn't distract from a solid first quarter.
Apr 27, 2018 by Brian Orelli, PhDBioMarin Cruises While It Waits on Seventh ApprovalThe FDA is expected to make a decision on pegvaliase on or before May 25.
Apr 27, 2018 by Brian Orelli, PhDWhy Seattle Genetics Jumped Higher TodayAn expanded approval of blood cancer drug Adcetris is paying off.
Apr 26, 2018 by Brian Orelli, PhDNatus Medical: A Tale of Two Halves of the Year?The medical device maker had a slow start, but management thinks it can pick things up.
Apr 25, 2018 by Brian Orelli, PhDBiogen Posts Double-Digit Profits, Has Cash to BurnSpinal muscular atrophy drug Spinraza makes up for declines in the biotech's multiple sclerosis drug franchise.
Apr 24, 2018 by Brian Orelli, PhDWhy Ionis Pharmaceuticals Crashed TodayTwo news events in one day have the biotech seeing red.
Apr 20, 2018 by Brian Orelli, PhDWhy Dicerna Rocketed Higher TodayInvestors are happy the biotech ended a lawsuit hanging over its head.
Apr 11, 2018 by Brian Orelli, PhDThis Little-Known Company Should Have Gilead's and Celgene's Investors NervousThere's a new kid on the CAR-T block.
Apr 9, 2018 by Brian Orelli, PhDWhy AVEO Oncology Jumped Higher TodayInvestors see value after last week's decline.
Apr 6, 2018 by Brian Orelli, PhDWhy Incyte and NewLink Genetics Crashed TodayThere's bad news on the clinical trial front.
Apr 3, 2018 by Brian Orelli, PhDWhy Flexion Therapeutics Jumped 12.6% TodayThere was good news on the payer front.
Apr 3, 2018 by Brian Orelli, PhDHow Worried Should Alnylam and Ionis Really Be About Pfizer's New Data?A battle for transthyretin amyloidosis patients is brewing.
Mar 26, 2018 by Brian Orelli, PhDDon't Worry, Pfizer Isn't Out of Options for Its Consumer Health Division Just YetA sale is looking less likely though.
Mar 26, 2018 by Brian Orelli, PhDThis Obesity Drugmaker Just Made a Comeback While Another Declared BankruptcyIt's all about the pipeline.
Mar 24, 2018 by Brian Orelli, PhDGilead Sciences' Investors Better Watch This Regeneron-Alnylam DealThe duo is looking to move into nonalcoholic steatohepatitis.
Mar 23, 2018 by Brian Orelli, PhDWhy Progenics Pharmaceuticals Sank TodayAn FDA delay has investors worried.
Mar 22, 2018 by Brian Orelli, PhDBetter Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam A matchup of platform drugmakers.
Mar 21, 2018 by Brian Orelli, PhDWhy It's So Dang Hard to Value Biotech DealsThere's more to the deals than the big headline numbers.
Mar 19, 2018 by Brian Orelli, PhDWhy Cannabis Producer Cronos Jumped 11.9% on MondayA cross-border deal has investors excited.
Mar 19, 2018 by Brian Orelli, PhDIs Pfizer's CEO Ian Read Really Worth 61% More?A retirement could be costly at this junction, but apparently so is keeping him around.
